AKIGAI’s mission
is clear and stedfast.
“To make an EGFR-inhibitor available to as many neuropathic pain patients as possible, as quickly as possible.”
To this end, we have mapped all marketed EGFR-inhibitors and >60 development candidates that have been tested in clinical trials.
After in-silico research, experiments in rodent models, as well as years of observations in 100+ successfully treated neuropathic pain patients with 11 different pain entities, one of the EGFR-inhibitors approved for the treatment of cancer stands out.
The EGFR is one of the most studied molecules in the human body.
The Two Routes of Administration
AKIGAI's approach is twofold. We envision two paths to development of a new type of EGFR-inhibitor.
Latest news from AKIGAI
AKIGAI featured in one of Europe’s largest Biotech outlet!
"AKIGAI, a Norway-based company, is hoping to change the narrative in neuropathic pain with EGFR inhibitors."
AKIGAI founders featured in Norway’s national newspapers
Serendipity, clinical acumen and relentless follow-up. Driven by dramatic patient experiences.
AKIGAI-gründerne oversvømmes av henvendelser fra leger og pasienter
"We want to signal hope and need to focus on developing our solution for all patients."
Collaborate with AKIGAI
AKIGAI is looking for partners and collaborators to help realize EGFR-inhibitors for use against neuropathic pain.
We are proud to be
working with
